Correale Michele, Magnesa Michele, Mazzeo Pietro, Fortunato Martino, Tricarico Lucia, Leopizzi Alessandra, Mallardi Adriana, Mennella Raffaele, Croella Francesca, Iacoviello Massimo, Di Biase Matteo, Brunetti Natale Daniele
Cardiology Unit, Cardio-Thoracic Department, Policlinico Riuniti University Hospital, Viale Luigi Pinto 1, 71100 Foggia, Italy.
Department of Medical and Surgical Sciences, University of Foggia, 71100 Foggia, Italy.
J Clin Med. 2023 Jan 30;12(3):1086. doi: 10.3390/jcm12031086.
(1) Background: Previous studies showed left ventricular (LV) and left atrial (LA) improvement and reverse remodeling after therapy with Sacubitril/Valsartan (S/V) in patients affected by heart failure with reduced ejection fraction (HFrEF). Therefore, we sought to investigate predictors of LA structural and functional reverse remodeling (LARR) in this setting of patients after therapy with S/V, focusing on left atrial strain parameters, such as peak atrial longitudinal strain (PALS). (2) Methods: Patients with HFrEF underwent clinical and echocardiographic evaluation at baseline and after six months of therapy with S/V. Measures of LA structure (LA volume index, LAVi) and function (LA emptying fraction (LAEF), PALS, LA conduit strain and peak atrial contraction strain (PACS) were also analyzed. Patients were divided in two groups, those with a LARR (relative reduction in LAVi > 15%, LARR+) and those without (LARR-). (3) Results: A total of 47 consecutive patients (66 ± 8 years, 85% male, mean LVEF 28 ± 6%) were enrolled in the study and followed up. A significant increase of LAEF (46 ± 13 vs. 37 ± 11%, < 0.001) and a significant reduction of LAVi (42 ± 15 vs. 45 ± 15 mL/m, = 0.008) were found after 6 months of S/V therapy; 47% of the population showed LA reverse remodeling. LA strain parameters, PALS (19 ± 8 vs. 15 ± 7 %, < 0.001) and LA conduit (-9.7 ± 5.2% vs. -7.6 ± 4.1%, = 0.007) significantly improved after 6 months of S/V therapy. At multivariable stepwise regression analysis, changes in LV End Diastolic Volume (LVEDV) and PALS were significantly proportional to changes in LAVi values. (4) Conclusions: Six months of treatment with S/V in patients with HFrEF was associated with an improvement in LA functional reverse remodeling in a real-world scenario. LARR was not significantly correlated to baseline echocardiographic variables, but was proportional to changes in LV volumes and LA strain parameters. Finally, after S/V therapy, a strict connection between LA and LV reverse remodeling and between LA anatomical and functional reverse remodeling seems to be outlined.
(1) 背景:既往研究表明,在射血分数降低的心力衰竭(HFrEF)患者中,沙库巴曲/缬沙坦(S/V)治疗后左心室(LV)和左心房(LA)有所改善且发生了逆向重构。因此,我们试图在接受S/V治疗的此类患者中研究左心房结构和功能逆向重构(LARR)的预测因素,重点关注左心房应变参数,如心房纵向应变峰值(PALS)。(2) 方法:HFrEF患者在基线时以及接受S/V治疗6个月后接受临床和超声心动图评估。还分析了左心房结构(左心房容积指数,LAVi)和功能(左心房排空分数(LAEF)、PALS、左心房管道应变和心房收缩峰值应变(PACS))的测量值。患者被分为两组,即发生LARR的患者(LAVi相对降低>15%,LARR+)和未发生的患者(LARR-)。(3) 结果:共有47例连续患者(66±8岁,85%为男性,平均左心室射血分数28±6%)纳入研究并接受随访。S/V治疗6个月后,LAEF显著增加(46±13%对37±11%,<0.001),LAVi显著降低(42±15对45±15 mL/m²,=0.008);47%的患者出现左心房逆向重构。S/V治疗6个月后,左心房应变参数PALS(19±8%对15±7%,<0.001)和左心房管道应变(-9.7±5.2%对-7.6±4.1%,=0.007)显著改善。在多变量逐步回归分析中,左心室舒张末期容积(LVEDV)和PALS的变化与LAVi值的变化显著相关。(4) 结论:在真实世界中,HFrEF患者接受6个月的S/V治疗与左心房功能逆向重构的改善相关。LARR与基线超声心动图变量无显著相关性,但与左心室容积和左心房应变参数的变化成比例。最后,在S/V治疗后,左心房和左心室逆向重构之间以及左心房解剖和功能逆向重构之间似乎存在紧密联系。